These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 21266799)

  • 1. Ustekinumab and herpes zoster.
    Failla V; Nikkels AF
    Dermatology; 2011; 222(2):119-22. PubMed ID: 21266799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on ustekinumab in moderate to severe plaque psoriasis.
    Croxtall JD
    Am J Clin Dermatol; 2012 Apr; 13(2):135-7. PubMed ID: 22201419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rapid onset of multiple squamous cell carcinomas in two patients commenced on ustekinumab as treatment of psoriasis.
    Young L; Czarnecki D
    Australas J Dermatol; 2012 Feb; 53(1):57-60. PubMed ID: 22309334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ustekinumab.
    Weber J; Keam SJ
    BioDrugs; 2009; 23(1):53-61. PubMed ID: 19344192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
    Reich K; Papp KA; Griffiths CE; Szapary PO; Yeilding N; Wasfi Y; Ott E; Hsu MC; Lebwohl M; Gordon KB;
    J Drugs Dermatol; 2012 Mar; 11(3):300-12. PubMed ID: 22395580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study.
    Gisondi P; Conti A; Galdo G; Piaserico S; De Simone C; Girolomoni G
    Br J Dermatol; 2013 May; 168(5):1124-7. PubMed ID: 23320916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response.
    Baerveldt EM; Onderdijk AJ; Kurek D; Kant M; Florencia EF; Ijpma AS; van der Spek PJ; Bastiaans J; Jansen PA; van Kilsdonk JW; Laman JD; Prens EP
    Br J Dermatol; 2013 May; 168(5):990-8. PubMed ID: 23278632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris.
    Clemmensen A; Spon M; Skov L; Zachariae C; Gniadecki R
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1037-40. PubMed ID: 21108668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ustekinumab for the treatment of moderate to severe psoriasis.
    Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ustekinumab (Stelara) for psoriasis.
    Med Lett Drugs Ther; 2010 Jan; 52(1330):7-8. PubMed ID: 20208473
    [No Abstract]   [Full Text] [Related]  

  • 11. Varicella zoster virus meningitis under ustekinumab because of plaque psoriasis.
    Stöllberger C; Finsterer J
    J Dermatol; 2017 Jun; 44(6):703-705. PubMed ID: 28150333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
    [No Abstract]   [Full Text] [Related]  

  • 13. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection.
    Tsai TF; Ho V; Song M; Szapary P; Kato T; Wasfi Y; Li S; Shen YK; Leonardi C;
    Br J Dermatol; 2012 Nov; 167(5):1145-52. PubMed ID: 22803615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.
    Lebwohl M; Leonardi C; Griffiths CE; Prinz JC; Szapary PO; Yeilding N; Guzzo C; Li S; Hsu MC; Strober B
    J Am Acad Dermatol; 2012 May; 66(5):731-41. PubMed ID: 21930328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.
    Uhlenhake EE; Feldman SR
    Expert Opin Biol Ther; 2010 Jul; 10(7):1105-12. PubMed ID: 20446825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
    Gordon KB; Papp KA; Langley RG; Ho V; Kimball AB; Guzzo C; Yeilding N; Szapary PO; Fakharzadeh S; Li S; Hsu MC; Reich K
    J Am Acad Dermatol; 2012 May; 66(5):742-51. PubMed ID: 21978572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes zoster in patients treated with biologicals.
    Failla V; Jacques J; Castronovo C; Nikkels AF
    Dermatology; 2012; 224(3):251-6. PubMed ID: 22677775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial.
    Wolf P; Weger W; Legat FJ; Posch-Fabian T; Gruber-Wackernagel A; Inzinger M; Salmhofer W; Hofer A
    Br J Dermatol; 2012 Jan; 166(1):147-53. PubMed ID: 21910714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial.
    Tsai TF; Song M; Shen YK; Schenkel B; Choe YB; Kim NI; Lee JH; Lee JH; Song HJ; Youn JI;
    J Drugs Dermatol; 2012 Aug; 11(8):943-9. PubMed ID: 22859239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Therapy for Psoriasis and the Risk of Herpes Zoster: A 500,000 Person-year Study.
    Shalom G; Zisman D; Bitterman H; Harman-Boehm I; Greenberg-Dotan S; Dreiher J; Feldhamer I; Moser H; Hammerman A; Cohen Y; Cohen AD
    JAMA Dermatol; 2015 May; 151(5):533-8. PubMed ID: 25797026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.